Equity
Total Liabilities & Equity
Regeneron Pharmaceuticals Total Liabilities & Equity increased by 0.8% to $40.87B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.9%, from $37.55B to $40.87B. Over 5 years (FY 2020 to FY 2025), Total Liabilities & Equity shows an upward trend with a 18.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026
How to read this metric
An increase typically reflects overall balance sheet growth or expansion of the company's asset base, while a decrease may indicate divestitures or debt repayment.
Detailed definition
This represents the sum of all claims against a company's assets, combining obligations to external creditors and the re...
Peer comparison
This is a standard accounting identity used across all industries to verify that assets equal the sum of liabilities and equity.
Metric ID:
total_liabilities_and_equityHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $21.49B | $23.67B | $25.43B | $26.35B | $27.21B | $27.68B | $29.21B | $30.06B | $30.66B | $32.16B | $33.08B | $34.37B | $36.09B | $37.44B | $37.76B | $37.55B | $38.22B | $40.17B | $40.56B | $40.87B |
| QoQ Change | — | +10.2% | +7.4% | +3.6% | +3.3% | +1.7% | +5.6% | +2.9% | +2.0% | +4.9% | +2.9% | +3.9% | +5.0% | +3.8% | +0.8% | -0.6% | +1.8% | +5.1% | +1.0% | +0.8% |
| YoY Change | — | — | — | — | +26.6% | +16.9% | +14.9% | +14.1% | +12.7% | +16.2% | +13.2% | +14.3% | +17.7% | +16.4% | +14.1% | +9.2% | +5.9% | +7.3% | +7.4% | +8.9% |
Range$21.49B – $40.87B
CAGR+14.5%
Avg YoY Growth+13.5%
Median YoY Growth+14.1%
Current Streak4 quarters growth
Total Liabilities & Equity at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's total liabilities & equity?
- Regeneron Pharmaceuticals (REGN) reported total liabilities & equity of $40.87B in Q1 2026.
- How has Regeneron Pharmaceuticals's total liabilities & equity changed year-over-year?
- Regeneron Pharmaceuticals's total liabilities & equity increased by 8.9% year-over-year, from $37.55B to $40.87B.
- What is the long-term trend for Regeneron Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's total liabilities & equity has grown at a 18.8% compound annual growth rate (CAGR), from $17.16B to $40.56B.
- What does total liabilities & equity mean?
- The total amount of money a company owes to others plus the value owned by its shareholders.